Stock Scorecard
Stock Summary for (CLVS) - $0.08 as of 9/1/2023 9:42:27 PM EST
Total Score
9 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CLVS
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CLVS
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CLVS
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for CLVS
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Financial Details for CLVS
Company Overview |
|
---|---|
Ticker | CLVS |
Company Name | |
Country | N/A |
Description | Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and marketing anticancer agents in the United States, the European Union, and internationally. The company is headquartered in Boulder, Colorado. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2022 |
Next Earnings Date | 11/7/2023 |
Stock Price History |
|
Last Day Price | 0.08 |
Last Day Price Updated | 9/1/2023 9:42:27 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 9,046,214 |
52-Week High | 3.25 |
52-Week Low | 0.04 |
Last Price to 52 Week Low | 100.00 % |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 43.96 |
Sector PE | 47.89 |
5-Year Average PE | -1.42 |
Free Cash Flow Ratio | 0.20 |
Industry Free Cash Flow Ratio | 12.58 |
Sector Free Cash Flow Ratio | 31.90 |
Current Ratio Most Recent Quarter | 0.14 |
Total Cash Per Share | 0.40 |
Book Value Per Share Most Recent Quarter | -2.89 |
Price to Book Ratio | 0.00 |
Industry Price to Book Ratio | 4.72 |
Sector Price to Book Ratio | 21.80 |
Price to Sales Ratio Twelve Trailing Months | 0.11 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.61 |
Sector Price to Sales Ratio Twelve Trailing Months | 3.72 |
Share Statistics |
|
Total Shares Outstanding | 144,955,000 |
Market Capitalization | 11,596,400 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00 % |
5-Year Dividend Payments Count | 0 |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00 % |
Annual Earnings Growth | 28.35 % |
Reported EPS 12 Trailing Months | 0.00 |
Reported EPS Past Year | -1.33 |
Reported EPS Prior Year | -2.29 |
Net Income Twelve Trailing Months | -251,904,000 |
Net Income Past Year | -264,524,000 |
Net Income Prior Year | -369,212,000 |
Quarterly Revenue Growth YOY | -19.10 % |
5-Year Revenue Growth | 25.34 % |
Balance Sheet |
|
Total Cash Most Recent Quarter | 58,320,000 |
Total Cash Past Year | 143,428,000 |
Total Cash Prior Year | 240,229,000 |
Net Cash Position Most Recent Quarter | -384,962,000 |
Net Cash Position Past Year | -728,838,000 |
Long Term Debt Past Year | 872,266,000 |
Long Term Debt Prior Year | 497,584,000 |
Total Debt Most Recent Quarter | 443,282,000 |
Equity to Debt Ratio Past Year | 0.00 |
Equity to Debt Ratio Most Recent Quarter | 0.00 |
Total Stockholder Equity Past Year | 129,000 |
Total Stockholder Equity Prior Year | 104,000 |
Total Stockholder Equity Most Recent Quarter | 145,000 |
Options |
|
Put/Call Ratio | 0.30 |
Has Options | False |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.00 |
MACD Signal | 0.00 |
20-Day Bollinger Lower Band | 0.00 |
20-Day Bollinger Middle Band | 0.00 |
20-Day Bollinger Upper Band | 0.00 |
Beta | 0.22 |
RSI | 0.00 |
50-Day SMA | 0.00 |
200-Day SMA | 0.00 |
System |
|
Modified | 9/27/2023 8:43:55 PM EST |